BOSTON, MA, Bambusa Therapeutics, a biotechnology company, announced the successful completion of its oversubscribed Series A financing of approximately $90 million.
Bambusa Therapeutics, a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders, announced the successful completion of its oversubscribed Series A financing of approximately $90 million. The round was led by new investor RA Capital Management, with participation from new investors including Janus Henderson Investors, Redmile Group, Invus, and ADAR1 Capital Management. All existing investors also participated.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
